Theravance Biopharma (TBPH) Misses Q4 EPS by 32c

Theravance Biopharma (NASDAQ: TBPH) reported Q4 EPS of ($2.02), $0.32 worse than the analyst estimate of ($1.70). Revenue for the quarter came in at $1.3 million versus the consensus estimate of $2.01 million.

For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• 51Talk Online Education Group (COE) Reports Q1 EPS of $0.00
• RH (RH) Tops Q1 EPS by 12c